Sector | Healthcare | Compare with Sector peers |
Industry | Pharmaceuticals & Drugs | Compare with Industry peers |
Website | http://www.aurobindo.com | |
Market Cap | 65,862.43 Cr. | |
Enterprise Value(EV) | 67,318.43 Cr. | 2023-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 47.28 | Trailing Twelve Months Ending 2023-12 |
Price-Earning Ratio (PE) | 23.77 | Trailing Twelve Months Ending 2023-12 |
Industry PE | 42.26 | Trailing Twelve Months Ending 2023-12 |
Book Value / Share | 497.17 | Trailing Twelve Months Ending 2023-12 |
Price to Book Value | 2.26 | Calculated using Price: 1,124.05 |
Dividend Yield | 0.27 | Period Ending 2023-03 |
No. of Shares Subscribed | 58.59 Cr. | 585,938,609 Shares |
FaceValue | 1 | |
About Aurobindo Pharma Ltd. | ||
Aurobindo Pharma continues to be one of the world's fastest growing Active Pharmaceutical Ingredients (API) manufacturing companies, driven by cost leadership, flexibility to produce multiple products in the same manufacturing facilities and capabilities in various therapeutic domains. Its API business has ensured the profitability and growth of its formulations business through seamless vertical integration. Its API business is supported by technologically advanced research and development infrastructure, which develops new products and plays a role in the delivery of products to the market. It has built a strong presence in key therapeutic segments such as Central nervous system (CNS), cardiovascular (CVS), anti-retroviral (ARV), anti-diabetics, gastroenterology and antibiotics. Also, it is building a diversified pipeline in high-margin specialty generic formulations segment. |
1 Day |
|
-4.60% |
1 Week |
|
-3.66% |
1 Month |
|
-1.25% |
3 Month |
|
+9.39% |
6 Month |
|
+27.00% |
1 Year |
|
+85.24% |
2 Year |
|
+81.04% |
5 Year |
|
+42.47% |
10 Year |
|
+271.20% |
9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | 35.29 | 32.53 | 27.63 | 23.02 | 18.49 | 18.52 | 27.53 | 11.38 | 7.5 | |
Return on Capital Employed (%) | 27.18 | 27.36 | 24.96 | 22.74 | 17.98 | 18.72 | 30.1 | 12.71 | 9.39 | |
Return on Assets (%) | 14.03 | 14.14 | 14.47 | 13.09 | 10.02 | 10.33 | 17.16 | 7.9 | 5.29 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
Shh. Funds | 5,156 | 7,287 | 9,372 | 11,680 | 13,891 | 16,825 | 21,930 | 24,576 | 26,840 | 28,189 | |
Non Curr. Liab. | 1,592 | 584 | 102 | 594 | 358 | 555 | 807 | 903 | 867 | 1,734 | |
Curr. Liab. | 6,136 | 7,840 | 6,606 | 8,666 | 12,021 | 11,385 | 10,665 | 8,156 | 11,494 | 13,012 | |
Minority Int. | 26 | 3 | 2 | 2 | 2 | 0 | -1 | -2 | 12 | 6 | |
Equity & Liab. | 12,910 | 15,714 | 16,082 | 20,942 | 26,271 | 28,765 | 33,401 | 33,633 | 39,213 | 42,941 | |
Non Curr. Assets | 4,611 | 5,420 | 6,875 | 8,764 | 10,939 | 12,352 | 13,578 | 15,510 | 17,667 | 19,386 | |
Curr. Assets | 8,299 | 10,294 | 9,206 | 12,178 | 15,332 | 16,413 | 19,740 | 18,044 | 21,460 | 23,555 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 12,910 | 15,714 | 16,082 | 20,942 | 26,271 | 28,765 | 33,401 | 33,633 | 39,213 | 42,941 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
Net Sales | 12,121 | 13,795 | 14,910 | 16,463 | 19,564 | 23,099 | 24,775 | 23,455 | 24,855 | 27,895 | |
Other Income | 97 | 204 | 116 | 102 | 155 | 192 | 381 | 323 | 291 | 601 | |
Total Income | 12,217 | 13,998 | 15,025 | 16,565 | 19,719 | 23,290 | 25,155 | 23,778 | 25,146 | 28,495 | |
Total Expenditure | -9,557 | -10,607 | -11,475 | -12,691 | -15,612 | -18,234 | -19,441 | -19,071 | -21,137 | -22,766 | |
PBIDT | 2,660 | 3,392 | 3,550 | 3,874 | 4,107 | 5,056 | 5,714 | 4,707 | 4,009 | 5,729 | |
Interest | -160 | -257 | -67 | -78 | -263 | -305 | -74 | -49 | -140 | -256 | |
Depreciation | -333 | -392 | -428 | -558 | -668 | -967 | -1,055 | -1,127 | -1,245 | -1,513 | |
Taxation | -597 | -721 | -760 | -818 | -727 | -899 | -2,010 | -726 | -685 | -1,113 | |
Exceptional Items | -88 | -26 | 2,815 | -128 | -70 | ||||||
PAT | 1,571 | 2,024 | 2,301 | 2,423 | 2,365 | 2,844 | 5,334 | 2,647 | 1,928 | 2,778 | |
Minority Interest | 5 | 2 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 3 | |
Share Associate | -10 | ||||||||||
Other Related Items | |||||||||||
Consolidated Net Profit | 1,576 | 2,025 | 2,302 | 2,423 | 2,365 | 2,845 | 5,335 | 2,648 | 1,928 | 2,770 | |
Adjusted EPS | 27 | 35 | 39 | 41 | 40 | 49 | 91 | 45 | 33 | 47 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | 646 | 1,237 | 1,420 | 3,279 | 1,955 | 1,651 | 4,381 | 3,329 | 5,016 | 2,387 | |
Cash Fr. Inv. | -819 | -1,398 | -1,445 | -1,787 | -1,927 | -2,903 | -1,568 | 599 | -3,212 | -3,978 | |
Cash Fr. Finan. | 118 | 93 | 365 | -1,915 | 864 | 1,919 | -1,947 | -1,365 | -2,969 | 1,814 | |
Net Change | -55 | -68 | 340 | -424 | 892 | 667 | 866 | 2,563 | -1,164 | 223 | |
Cash & Cash Eqvt | 148 | 461 | 744 | 320 | 1,210 | 1,876 | 2,747 | 5,330 | 4,163 | 4,392 |
Mon, 06 May 2024
Scheme of Arrangement Aurobindo Pharma Limited has informed the Exchange about receipt of NCL Order approving the Scheme of Amalgamation |
Fri, 03 May 2024
Updates Aurobindo Pharma Limited has informed the Exchange regarding 'With reference to the above, we are submitting all the required details as per SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 with regard to an order received from the Deputy Commissioner, Punjagutta (ST) STU-1 of GST, Punjagutta Division, Hyderabad under the provisions of the Central Goods and Services Tax Act, 2017 and TGST Act 2017 for the FY 2018-19 demanding reversal of ITC and payment of GST amounting to Rs. 6,54,50,645 along with interest of Rs.5,92,20,900 and also levying a penalty of Rs. 65,51,354/-, the disclosure of which was submitted on May 2, 2024.'. |
Fri, 03 May 2024
Updates Aurobindo Pharma Limited has informed the Exchange regarding 'Completion of US FDA Inspection at Unit II of Eugia Pharma Specialities Ltd. a wholly owned subsidiary of the Company'. |
Mon, 06 May 2024 |
Opening at Low |
Making Lower Lows for 3 days |
Close Within 52 Week High Zone |
Making Higher Highs for 2 Days |
Making Lower Lows for 2 Days |